Uroplakin II Expression in Breast Carcinomas Showing Apocrine Differentiation: Putting Some Emphasis on Invasive Pleomorphic Lobular Carcinoma as a Potential Mimic of Urothelial Carcinoma at Metastatic Sites

Table 3

Summary of immunoreactivity of IPLC, cILC, AC, and AM for each immunohistochemical marker used in this study.

Score	Uroplakin II	GATA3	p63	p40	CK7	CK20	34βE12	GCDFP-15
IPLC ()
3+	3 (50%)	5 (83%)	0	0	21 (100%)	0	21 (100%)	21 (100%)
2+	2 (33%)	1 (17%)	0	0	0	0	0	0
1+	1 (17%)	0	2 (33%)	2 (33%)	0	0	0	0
0	0	0	4 (67%)	4 (67%)	0	21 (100%)	0	0
cILC ()
3+	0	10 (100%)	0	0	10 (100%)	0	10 (100%)	0
2+	0	0	0	0	0	0	0	1 (10%)
1+	0	0	1 (10%)	1 (10%)	0	0	0	6 (60%)
0	10 (100%)	0	9 (90%)	9 (90%)	0	10 (100%)	0	3 (30%)
AC ()
3+	5 (50%)	5 (50%)	0	0	10 (100%)	0	0	10 (100%)
2+	2 (20%)	3 (30%)	0	0	0	0	0	0
1+	3 (30%)	2 (20%)	0	0	0	0	0	0
0	0	0	10 (100%)	10 (100%)	0	10 (100%)	10 (100%)	0
AM ()
3+	5 (100%)	0	0	0	5 (100%)	0	0	5 (100%)
2+	0	0	0	0	0	0	0	0
1+	0	1 (20%)	0	0	0	0	0	0
0	0	4 (80%)	5 (100%)	5 (100%)	0	5 (100%)	5 (100%)	0

IPLC: invasive pleomorphic lobular carcinoma; cILC: classic invasive lobular carcinoma; AC: apocrine carcinoma; AM: apocrine metaplasia.